GUIDED EVALUATION
Test Medimapper with your own products.
Start with a Five-Product Market Match or Portfolio Presence Scan. We review coverage first, prepare a focused proof and only then configure a three-day evaluation when it fits the workflow.
No generic demo and no unqualified self-service trial. A sample comparison of quetiapine, risperidone and olanzapine is available to download first.
START WITH THE CURRENT QUESTION
Tell us what your team is evaluating.
01
Five-Product Market Match
For wholesalers, distributors and import-export teams.
You provide five products, a source market and the target regions you need to compare We prepare comparable product candidates, visible pack and code differences and relevant source context
Compare 5 products →
02
Portfolio Presence Scan
For manufacturers, brands, portfolio and business-development teams.
You provide ten products or substances and the target regions you want to review We prepare comparable presentations, packs, manufacturers, brands and product-presence patterns
Scan a portfolio →
03
API evaluation
Available from 1 October 2026.
For data, software and integration teams Connect national records and match results to your own systems Review coverage, sample responses and how production access will work
FROM PROOF TO SUBSCRIPTION
A focused evaluation with a defined result.
01 Submit the use case Tell us which products, markets and decision the evaluation must support.
02 We review coverage We confirm whether the required countries, fields and data depth can support a credible proof.
03 See a product-specific proof We walk through a focused result using your products and markets, including relevant limitations.
04 Agree the evaluation When the proof fits, we define users, access channels, success criteria and the three-day access window.
05 Review the result The evaluation ends with a scheduled result call and a decision about regional subscription scope.
EVALUATION REQUEST
Tell us what you need to compare.
We use this information to review coverage and prepare the right proof. Fields marked optional can be completed during the first conversation.
***
Trial and proof access is subject to approval. It does not grant permission to redistribute data or use results as clinical, regulatory, quality or legal determinations.